IVVD — Invivyd, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1832038 ·
Last close
$1.10
Market Cap
$324.07M
52W High
$2.04
52W Low
$1.02
ADV30
2,439,344
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 13,744,000 | 12,712,000 | -43,136,000 | -41,400,000 | 241,742,000 | 184,153,000 | 38,692,000 |
| Dec 2025 | 17,207,000 | 16,067,000 | -12,555,000 | -11,070,000 | 276,883,000 | 226,689,000 | 35,343,000 |
| Sep 2025 | 13,129,000 | 12,041,000 | -11,023,000 | -10,470,000 | 139,158,000 | 84,967,000 | 46,090,000 |
| Jun 2025 | 11,786,000 | 11,101,000 | -15,060,000 | -14,660,000 | 89,138,000 | 34,905,000 | 46,349,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-58,135,000
Investing CF
$-155,000
Financing CF
$215,630,000
CapEx
$-160,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-954,483,000
Inventory
$263,000
Receivables
$14,595,000
ST Investments
—
EBIT TTM
$-55,560,000
Pretax Income TTM
$-52,489,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$55,866,000
EBITDA
$-81,157,000
Free Cash Flow
$-50,099,752
Enterprise Value
$148,541,200
Total Cash
$184,152,992
Total Debt
$8,626,000
Shares Out
294,607,452
Trailing EPS
$-0.29
Book Value
$0.72
ROE
-60.3%
ROA
-29.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 53,426,000 | -55,560,000 | -52,489,000 | 276,883,000 | 35,343,000 | — | -58,135,000 |
| Dec 2024 | 25,384,000 | -176,876,000 | -169,925,000 | 129,515,000 | 61,976,000 | — | -170,491,000 |
| Dec 2023 | 0 | -207,783,000 | -198,643,000 | 229,181,000 | 51,713,000 | — | -173,164,000 |
| Dec 2022 | 0 | -226,258,000 | -241,317,000 | 383,167,000 | 27,197,000 | — | -219,987,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | $326.21M | $6.31 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $321.59M | $1.29 | — |
| NMRA | Neumora Therapeutics, Inc. | $340.92M | $1.84 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $343.55M | $9.89 | — |
| PALI | PALISADE BIO, INC. | $345.42M | $1.99 | — |
News headlines (Yahoo Finance, 1h cache)
Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now
2026-05-18 04:49 · Yahoo
Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments
2026-05-14 23:01 · Yahoo
Invivyd Q1 Earnings Call Highlights
2026-05-14 16:15 · Yahoo
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
2026-05-14 12:15 · Yahoo
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-14 11:01 · Yahoo
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
2026-05-13 12:20 · Yahoo
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
2026-05-12 21:15 · Yahoo
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
2026-05-11 11:01 · Yahoo
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
2026-05-07 11:01 · Yahoo
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-05 11:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.